Diagnostics News and Research

RSS

Roche extends cash tender offer to acquire all shares of Illumina

Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc., at a price of $44.50 per share, to 6:00 p.m., New York City time, on March 23, 2012.

From Illumina, Inc. 27 Feb 2012

New process can create LEDs that produce light in the UV range

A multinational team of scientists has developed a process for creating glass-based, inorganic light-emitting diodes (LEDs) that produce light in the ultraviolet range. The work, reported this week in the online Nature Communications, is a step toward biomedical devices with active components made from nanostructured systems.

27 Feb 2012

UA researchers identify the likely culprit of epilepsy

Only 10 years ago, deciphering the genetic information from one individual in a matter of weeks to find a certain disease-causing genetic mutation would have been written off as science fiction. It was the time of the Human Genome Project, and it had taken armies of sequencing robots working around the clock for almost a decade to unravel the complete sequence of the human genetic code - referred to as the genome - by churning out the DNA alphabet letter by letter.

24 Feb 2012

Self-propelled devices through the bloodstream a reality

Someday, your doctor may turn to you and say, "Take two surgeons and call me in the morning." If that day arrives, you may just have Ada Poon to thank.

23 Feb 2012

Roche grants in vitro diagnostics product license for real-time PCR technology to LTC

Roche and Life Technologies Corporation announced today that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.

23 Feb 2012

New microfluidic device can rapidly isolate target cells

Separating complex mixtures of cells, such as those found in a blood sample, can offer valuable information for diagnosing and treating disease. However, it may be necessary to search through billions of other cells to collect rare cells such as tumor cells, stem cells or fetal cells. "You're basically looking for a needle in a haystack," says Sukant Mittal, a graduate student in the Harvard-MIT Division of Health Sciences and Technology.

23 Feb 2012

China's SFDA approves Dynex DS2 ELISA analyzer

Dynex Technologies announced today it has received approval from China's State Food and Drug Administration (SFDA) to market the DS2 automated enzyme-linked immunosorbent assay (ELISA) analyzer in China.

From Thermo Fisher Scientific Inc. 22 Feb 2012

NYSDOH approves Enzo Biochem's ColonSentry test

Enzo Biochem, Inc. today announced that the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry test for providing an assessment of a patient's risk of having colorectal cancer.

22 Feb 2012

DANSR/FORTE assay more effective in diagnosing Edwards and Down syndrome

Using a noninvasive test on maternal blood that deploys a novel biochemical assay and a new algorithm for analysis, scientists can detect, with a high degree of accuracy, the risk that a fetus has the chromosomal abnormalities that cause Down syndrome and a genetic disorder known as Edwards syndrome.

22 Feb 2012

Comprehensive mobile solution to deliver enhanced care to patients

Verizon Enterprise Solutions, Motorola Mobility Inc. and BoxTone are collaborating to develop a comprehensive mobile solution to help satisfy the unique security, reliability and usability requirements of the health care industry. By providing health care practitioners with secure mobile devices and apps, patient care can be improved through the sharing of clinical data in near-real time to help speed decision making and control costs.

21 Feb 2012

Axway-GE Healthcare combined HIE solution selected by HITE-CT

Axway, the Business Interaction Networks company, and GE Healthcare, a leading health information exchange software provider and a division of General Electric Company announced today that the Health Information Technology Exchange of Connecticut (HITE-CT), the state designated Health Information Exchange (HIE), has selected its combined solution for HIE.

20 Feb 2012

ASI receives FDA clearance for GenASIs Scan and Analysis

Applied Spectral Imaging (ASI) announces that ASI's GenASIs automated scanning and image analysis system for detection and quantifying chromosome 17 and the HER-2/neu gene has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US.

20 Feb 2012

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

Evolution of cancer genome to be discussed at 2012 AAAS annual meeting

Professor Mike Stratton, Director of the Wellcome Trust Sanger Institute, will speak about 'the evolution of the cancer genome' at the prestigious 2012 American Association for the Advancement of Science annual meeting. The AAAS annual meeting is one of the world's most widely recognized science events.

19 Feb 2012

Abbott increases quarterly common dividend to 51 cents per share

The board of directors of Abbott today increased the company's quarterly common dividend from 48 cents per share to 51 cents per share.

18 Feb 2012

Asuragen introduces miRInform test for diagnosis of pancreatic ductal adenocarcinoma

Asuragen, Inc. announced today the immediate availability of the miRInform® Pancreas Test in its CAP-accredited CLIA Laboratory. miRInform® Pancreas was developed to aid physicians in the diagnosis and management of pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive. The test evaluates expression levels of seven miRNAs in Fine Needle Aspirate (FNA) specimens of pancreatic masses.

17 Feb 2012

Abcodia, Volition announce collaboration agreement

VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces a collaboration agreement with Abcodia, a specialist company spun out from University College London (UCL), under which Volition will gain access to Abcodia's biobank of over 5,000,000 human serum samples to validate its suite of NuQ tests.

17 Feb 2012

Researchers sequence genome of Tasmanian devil contagious cancer

Researchers have sequenced the genome of a contagious cancer that is threatening the Tasmanian devil, the world's largest carnivorous marsupial, with extinction. Cataloguing the mutations present in the cancer has led to clues about where the cancer came from and how it became contagious.

17 Feb 2012

First accurate predictive model to differentiate between dengue fever and dengue hemorrhagic fever

Researchers at the University of Texas Medical Branch have developed the first accurate predictive model to differentiate between dengue fever (DF) and its more severe form, dengue hemorrhagic fever (DHF).

17 Feb 2012

Illumina introduces Cancer Analysis Service from IGN

Illumina, Inc. today announced the launch of a Cancer Analysis Service from the Illumina Genome Network (IGN) that leverages the high accuracy of Illumina technologies to provide cancer researchers with easily interpretable tumor/normal sequencing data to quickly move their research forward.

From Illumina, Inc. 16 Feb 2012